|
Publications |
|
Selected publications from the lab (*equal contribution)
▪ C.J. LaCasse, N. Janikashvilli, C.B. Larmonier, D. Alizadeh, N.T. Hanke, J. Kartchner, E. Situ, S. Centuori, M. Harnoy, B. Bonnotte, E. Katsanis* and N. Larmonier*. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFNg-dependent mechanism. The Journal of Immunology. 187: 6310-6317. 2011.
D. Lakomy/N. Janikashvili, J. Fraszczak, M. Trad, S. Audia, M. Samson, M. Ciudad, J. Vinit, C. Vergely, D. Caillot, P. Foucher, L. Lagrost, S. Chouaib, E. Katsanis, N. Larmonier* and B. Bonnotte*. Cytotoxic dendritic cells generated from cancer patients. The Journal of Immunology. 187: 2775-2782. 2011.
N. Janikashvili*, C. LaCasse*, M. Trad, A. Herrell, S. Bustamante, M. Har-Noy, N. Larmonier*, E. Katsanis* . Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T cells and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood. 117: 1555-1564. 2011
▪ N. Janikasvili, B. Bonnotte, E. Katsanis and N. Larmonier. The dendritic cell-regulatory T lymphocyte cross-talk contributes to tumor-induced tolerance. Clinical and Developmental Immunology. 2011: 430394, 1-14. 2011.
▪ J. Fraszczak, M. Trad, D. Lakomy, D. Cathelin, N. Janikashvili, N. Sassi, V. Granci, A. Morizot, S. Audia, L. Lagrost, E. Katsanis, E. Solary, B. Bonnotte* and N. Larmonier*. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. The Journal of Immunology. 184: 1876-1884. 2010
▪ J. Cantrell, C. Larmonier, N. Janikashvili, S. Bustamante, J. Fraszczak, A. Herrell, T. Lundeen, C. J. LaCasse, E. Situ, N. Larmonier* and E. Katsanis*. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology. 215: 534-544. 2010
▪ N. Larmonier, J. Fraszczak, D. Lakomy, B. Bonnotte and E. Katsanis. Killer dendritic cells and their potential for cancer immunotherapy (Review). Cancer Immunology and Immunotherapy. 59: 1-11. 2010
▪ N. Larmonier, N. Janikashvili, C. J. LaCasse, C. Larmonier, J. Cantrell, E. Situ, T. Lundeen, B. Bonnotte and E. Katsanis. Imatinib mesylate suppresses CD4+CD25+ regulatory T cells and efficiently combines with immunotherapy to treat BCR-ABLnegative tumors. The Journal of Immunology. 181: 6955-6963. 2008
▪ N. Larmonier, J. Cantrell, G. Li, C. LaCasse, N. Janikashvili, E. Situ, M. Sepassi, S. Andreansky and E. Katsanis. Chaperone rich tumor cell lysate-mediated activation of antigen presenting cells resists regulatory T cell suppression. Journal of Leukocyte Biology, 83: 1049-1059. 2008
▪ N. Larmonier, M. Marron, Y. Zeng, J. Cantrell, A. Romanoski, M. Sepassi, S. Thompson, X. Chen, S. Andreansky, and E. Katsanis. Tumor-derived CD4+CD25+ regulatory T cells suppression of dendritic cell function involves TGF-b and IL-10. Cancer Immunology and Immunotherapy. 56: 48-59. 2007.
▪ Feng H., Zeng Y., Graner M.W., Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 100: 4108-4115, 2002.
▪ Feng H., Zeng Y., Graner M.W., Likhacheva A., Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate anti-tumor immunity. Blood 101: 245-252, 2003.
▪ Zeng Y., Feng H., Graner M.W., Katsanis E. Tumor-derived chaperone-rich cell lysates activate dendritic cells and elicit potent anti-tumor immunity. Blood 101: 4485-4491, 2003.
▪ Zeng Y., Graner M.W., Li G., Feng H., Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate loaded dendritic cells to treat bcr-abl+ murine leukemia. International Journal of Cancer 100:251-259, 2004.
▪ Zeng Y., Graner M.W., Thompson S., Marron M., Katsanis E. Induction of bcr-abl specific immunity following vaccination with chaperone rich cell lysates derived from bcr-abl+ tumor cells. Blood 105: 2016-2022, 2005.
Listing of peer-reviewed publications:
|
|
Emmanuel Katsanis and Nicolas Larmonier Steele Children’s Research Center University of Arizona |
|
Tumor Immunology |
